<?xml version='1.0' encoding='utf-8'?>
<document id="28940241"><sentence text="Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography."><entity charOffset="13-18" id="DDI-PubMed.28940241.s1.e0" text="OATPs" /><entity charOffset="45-54" id="DDI-PubMed.28940241.s1.e1" text="Erlotinib" /><pair ddi="false" e1="DDI-PubMed.28940241.s1.e0" e2="DDI-PubMed.28940241.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28940241.s1.e0" e2="DDI-PubMed.28940241.s1.e1" /></sentence><sentence text="To assess the hepatic disposition of erlotinib, we performed positron emission tomography (PET) scans with [11 C]erlotinib in healthy volunteers without and with oral pretreatment with a therapeutic erlotinib dose (300â€‰mg)"><entity charOffset="37-46" id="DDI-PubMed.28940241.s2.e0" text="erlotinib" /><entity charOffset="199-208" id="DDI-PubMed.28940241.s2.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28940241.s2.e0" e2="DDI-PubMed.28940241.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28940241.s2.e0" e2="DDI-PubMed.28940241.s2.e1" /></sentence><sentence text=" Erlotinib pretreatment significantly decreased the liver exposure to [11 C]erlotinib with a concomitant increase in blood exposure, pointing to the involvement of a carrier-mediated hepatic uptake mechanism"><entity charOffset="1-10" id="DDI-PubMed.28940241.s3.e0" text="Erlotinib" /></sentence><sentence text=" Using cell lines overexpressing human organic anion-transporting polypeptides (OATPs) 1B1, 1B3, or 2B1, we show that [11 C]erlotinib is selectively transported by OATP2B1"><entity charOffset="80-88" id="DDI-PubMed.28940241.s4.e0" text="OATPs" /></sentence><sentence text=" Our data suggest that at PET microdoses hepatic uptake of [11 C]erlotinib is mediated by OATP2B1, whereas at therapeutic doses OATP2B1 transport is saturated and hepatic uptake occurs mainly by passive diffusion"><entity charOffset="128-135" id="DDI-PubMed.28940241.s5.e0" text="OATP2B1" /></sentence><sentence text=" We propose that [11 C]erlotinib may be used as a hepatic OATP2B1 probe substrate and erlotinib as an OATP2B1 inhibitor in clinical drug-drug interaction studies, allowing the contribution of OATP2B1 to the hepatic uptake of drugs to be revealed"><entity charOffset="86-95" id="DDI-PubMed.28940241.s6.e0" text="erlotinib" /><entity charOffset="192-199" id="DDI-PubMed.28940241.s6.e1" text="OATP2B1" /><pair ddi="false" e1="DDI-PubMed.28940241.s6.e0" e2="DDI-PubMed.28940241.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28940241.s6.e0" e2="DDI-PubMed.28940241.s6.e1" /></sentence><sentence text="" /></document>